Figure_5.tif (1.41 MB)

Kinome response to targeted MEK and IKK inhibitor treatment.

Download (0 kB)
figure
posted on 24.06.2013 by Matthew J. Cooper, Nathan J. Cox, Eric I. Zimmerman, Brian J. Dewar, James S. Duncan, Martin C. Whittle, Thien A. Nguyen, Lauren S. Jones, Sreerupa Ghose Roy, David M. Smalley, Pei Fen Kuan, Kristy L. Richards, Richard I. Christopherson, Jian Jin, Stephen V. Frye, Gary L. Johnson, Albert S. Baldwin, Lee M. Graves

(A) MYL-R cells were treated for 24 hours with AZD6244 (AZD, 5 µM), BAY 65-1942 (BAY, 10 µM) or AZD (5 µM) plus BAY (10 µM), and kinases were isolated and quantified by MIB/MS in two independent experiments. The relative abundances (Drug/DMSO) of kinases in the MEK/ERK pathway are shown. Error bars, SE (N = 2). (B) MYL-R cells were treated for 24 hours with AZD (5 µM), BAY(10 µM) or AZD (5 µM) plus BAY (10 µM), and were analyzed by immunoblot using the antibodies indicated. Data are representative of three separate experiments. (C) MYL-R cells were treated for 12 hours with AZD (5 µM), BAY (10 µM), AZD (5 µM) plus BAY (10 µM), or dasatinib (1 nM). Total RNA was isolated and the expression of IκBα and IL-6 were evaluated by qRT-PCR. Error bars, SE (N = 2).

History

Licence

Exports